Heparin Market Analysis Report By Type, By Route of Administration, By Application Form, By End Use And Segment Forecasts From 2019 To 2026

Industry Insights

The global Heparin market size was valued at USD 6.49 billion in 2018. It is also estimated to witness a 1.6% CAGR over the forecasted period, 2019 to 2026. Rising incidences associated with cardiovascular disorders and venous thromboembolism are anticipated to drive the market growth.

The data published by the CDC (Centers for Disease Control), in 2018 stated that more than 900,000 people across the U.S. were affected by pulmonary embolism and vein thrombosis each year. These factors are anticipated to trigger market demand in the upcoming years.

Several biopharmaceutical companies have started investing hugely in R&D activities for new drug development. Also, organizations like NIH (National Institutes of Health) and CDC have started undertaking initiatives to increase the level of awareness among the individuals residing in the developing economies. Moreover, the rising demand for anticoagulants is also expected to boost the market growth.

Type Insights

The global heparin market can be classified into unfractionated heparin, ultra-low molecular weight, and low molecular weight based on its type. In 2018, the segment of low molecular weight accounted for the highest share across the global market. This can be associated with the enhanced anticoagulant effect associated with these products.

A study by NEJM Journal Watch stated that reduced incidences of thrombocytopenia by induction of heparin have also contributed majorly towards increasing demand for this segment. The segment of ultra-low molecular weight is projected to account for the highest CAGR from 2019 to 2026 due to its enhanced pharmacological effects and product commercialization.

Route of Administration Insights

The global market can be segmented into subcutaneous and intravenous segments based on the route of administration. In 2018, the subcutaneous segment accounted for the largest share across the global market. It is also projected to register significant growth in the upcoming years on account of the low hospitalization costs involved in this drug route.

Moreover, the subcutaneous route of administration is generally preferred by the patients due to ease of drug administration, increasing preference for in-house treatment, and reduced time associated with the treatment. Also, the reduction in the number of risks associated with systemic infection and enhanced quality of life is projected to trigger the market growth for this segment.

Application Insights

The global market can be segmented into atrial fibrillation, coronary artery disease, venous thromboembolism, and renal impairment based on its application. In 2018, the coronary artery disease segment accounted for the highest share across the global market on account of the rising number of incidences and prevalence of heart disorders.

The segment of venous thromboembolism is anticipated to witness the highest CAGR from 2019 to 2026. This segment can be further bifurcated into DVT (deep vein thrombosis) and PE (pulmonary embolism). Rising awareness about thrombosis among the millennial population is expected to augment the market growth for this segment.

End-Use Insights

The global market can be classified into outpatients and inpatients based on its end-use. In 2018, the outpatient end-user segment accounted for the largest share across the global market. It is also expected to possess the highest CAGR of 2.4% from 2019 to 2026.

This growth can be associated with the rising preference of the subcutaneous drug administration route prevailing among the population. The reduction in the hospital costs for the outpatient segment is expected to propel its market demand across the globe. Also, studies conducted by NCBI stated that outpatient therapy was less costly venous thromboembolism.

Regional Insights

North America accounted for a dominant share across the global market in 2018. This can be associated with the surging number of cardiovascular disorders and sports injuries among individuals residing across this region. Moreover, an increase in the expenditure on the healthcare sector enhanced healthcare infrastructure, and higher patient awareness is expected to further fuel up market growth.

The Asia Pacific is expected to witness the fastest growth across the global market from 2018 to 2026. This growth can be attributed to several factors such as improved healthcare infrastructure, emerging opportunities, several initiatives being undertaken by public and private organizations, and economic development across countries like China, India, and Japan are anticipated to augment the market demand in the upcoming years.

COVID-19 Impact Insights

The heparin market has been positively impacted due to the ongoing COVID-19 pandemic. An increase in the budget and expenditure on healthcare departments by the government across several countries has contributed majorly towards the market growth. Moreover, the rising number of cases across the globe has forced governing organizations to home isolate asymptomatic patients. This has triggered the demand for subcutaneous drugs. Also, as people having cardiovascular problems are being considered under the high-risk category, their care is the utmost priority of several countries. Such factors have also promoted new entrants to make huge investments for catering to the rising needs across the globe.

Heparin Market Share Insights

The key players operating in the market are Pfizer, Inc., Leo Pharma A/S, GlaxoSmithKline plc, Baxter, Sanofi, Aspen Holdings, Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, and B. Braun Medical Inc. They are constantly engaged in product development and innovation to gain a cutting edge over other players.

Strategic initiatives such as acquisitions, mergers, and collaborations are also being undertaken by these players for widening the global product portfolio. For example, Fresenius Kabi had launched the heparin sodium in free flex bags that are ready-to-administer for expansion of their critical care products portfolio.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends from 2014 to 2026 in each of the sub-segments. For this study, Million Insights has segmented the global heparin market based on type, route of administration, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2014 - 2026)
    • Low Molecular Weight Heparin
    • Ultra-low Molecular Weight Heparin
    • Unfractionated Heparin

• Route of Administration Outlook (Revenue, USD Million, 2014 - 2026)
    • Intravenous
    • Subcutaneous

• Application Outlook (Revenue, USD Million, 2014 - 2026)
    • Venous Thromboembolism
    • Atrial Fibrillation
    • Renal Impairment
    • Coronary Artery Disease
    • Others

• End-Use Outlook (Revenue, USD Million, 2014 - 2026)
    • Outpatient
    • Inpatient

• Regional Outlook (Revenue, USD Million, 2014 - 2026)
    • North America
        • U.S.
        • Canada
    • Europe
        • Germany
        • France
        • U.K.
        • Italy
        • Spain
        • Russia
    • the Asia Pacific
        • Japan
        • China
        • India
        • South Korea
        • Australia
        • Singapore
    • Latin America
        • Brazil
        • Mexico
        • Argentina
    • Middle East & Africa
        • South Africa
        • Saudi Arabia
        • UAE